Trial IRCT20190727044343N1
Publication Davoodi L, Int J Clin Pract, 2020 (published paper)
Dates: 2020-03-15 to 2020-03-27
Funding: Public/non profit (Mazandaran University of Medical Science, Sari, Iran)
Conflict of interest: No
| Methods | |
| RCT Blinding: double blinding | |
| Location :
Single center / Iran Follow-up duration (days): 14 | |
| Inclusion criteria | 1. chest CT finding compatible with COVID-19 infection along with other symptoms of coronavirus infection. Bilateral and peripheral ground-glass and consolidative pulmonary opacities were the hallmarks of CT findings. 2. any symptoms of respiratory tract involvement including cough, dyspnea or tachypnea along with a history of contact with a known case of COVID-19 3. creatinine clearance greater than 60 ml/min. |
| Exclusion criteria | 1. Suspicious patients for COVID-19 pneumonia who had severe underlying diseases such as cardiovascular, lung and kidney diseases, 2. patients with severe pneumonia needing hospitalization, 3. patient who were unable to take oral medications and 4. concurrent use of azathioprine, didanosine, mercaptopurine or pegloticase (due to drug interaction with FBX). |
| Interventions | |
| Treatment
Febuxostat 80 mg orally once a day for 5 days |
|
| Control
Hydroxychloroquine (200 mg) Duration : 5 days | |
| Participants | |
| Randomized 60 participants (n1=30 / n2= 30) | |
| Characteristics of participants N=60 Mean age : 57.7 32 males Severity : Mild: n=0 / Moderate: n=0/ Severe: n=0 Critical: n=0 | |
| Primary outcome | |
| In the register CT-scan findings Before the intervention and 2 weeks after the intervention | |
| In the report rate of hospitalization. | |
| Documents available |
Protocol NR Statistical plan NR Data-sharing stated
|
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
|
| General comment |